Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of
patients worldwide. Despite all the efforts to understand its pathogenesis and develop new …

The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic
shift since the dawn of the current century. This has been driven largely by the introduction of …

Despite recent advances in immunotherapies targeting single tumor-associated antigens,
patients with multiple myeloma eventually relapse. ISB 2001 is a CD3+ T cell engager (TCE) …

T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific
antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with …

Bispecific antibodies are monoclonal antibodies targeting both a surface molecule on the
malignant plasma cells and CD3 on T cells, leading to tumor cell death by activated T cells …

Background CD38 has been established as an important therapeutic target for multiple
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …

For patients with relapsed/refractory multiple myeloma with a relapse after B-cell maturation
antigen (BCMA)–directed chimeric antigen receptor T-cell therapy (CAR-T), optimal salvage …

Objectives This paper reviews current and emerging therapies for multiple myeloma (MM).
Methods Narrative review. Results MM is a complex, heterogenous condition, and in recent …

In recent years, the treatment landscape of multiple myeloma has continued to evolve with
the introduction of novel immunotherapies. This progress has translated to improved overall …

Over the past couple of decades, the life expectancy of patients with multiple myeloma (MM)
has progressively increased, however, the disease per se remains incurable. This has …